Lv45
602 积分 2022-10-10 加入
Deriving acceptable limits for non-mutagenic impurities in medicinal products – Durational adjustments
13分钟前
待确认
Volume of Distribution in Drug Design
22天前
已完结
Development of a MMAE-based antibody-drug conjugate targeting B7–H3 for glioblastoma
1个月前
已完结
A multi-scale numerical study of monoclonal antibodies uptake by initial lymphatics after subcutaneous injection
2个月前
已完结
Predicting Human Bioavailability of Subcutaneously Administered Fusion Proteins and Monoclonal Antibodies Using Human Intravenous Clearance or Antibody Isoelectric Point
2个月前
已完结
Transport and Lymphatic Uptake of Biotherapeutics Through Subcutaneous Injection
2个月前
已完结
Challenging the Norm: A Multidisciplinary Perspective on Intravenous to Subcutaneous Bridging Strategies for Biologics
2个月前
已完结
Challenging the Norm: A Multidisciplinary Perspective on Intravenous to Subcutaneous Bridging Strategies for Biologics
2个月前
已完结
Toxicokinetic and toxicodynamic considerations when deriving health-based exposure limits for pharmaceuticals
2个月前
已完结
A DXd/TLR7-agonist dual-conjugate anti-HER2 ADC exerts robust anti-tumor activity through tumor cell killing and immune activation
2个月前
已完结
皖公网安备34019202002308
